



HHCP-I Cryopreserved Plateable Human Hepatocytes for Induction Assays
Cell Specification – Certificate of Analysis (CoA)

Lot HH140704

Batch Release: Sept 28, 2020

Species: Human	Gender: male Size: 168 cm Non-smoker	Age: 68 years Weight: 95 kg
Serology: HAV, HBV, HCV, HIV 1/2: negative	Diagnosis: CCC (Cholangiocellular carcinoma)	
Medical History: Diabetes, Hypertension	Therapy: liver resection	
Medication: Metformin, Bisoprolol, Atorvastatin, Omeprazol, Enoxaparin, Tilidin, Sympal		
Cryopreservation: Date: July 04, 2014 Amount per vial: 9.08×10^6 cells	Thawing: n=2 Post-thaw viability: 84.2 ± 7.0 % Post-thaw yield per vial: $3.7 \pm 1.0 \times 10^6$ cells Recovery: 41 ± 11 %	
Phase contrast on day 1 after thawing (24well plate)	Phase contrast on day 3 after thawing (24well plate)	
		

Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5×10^6 cells in 0.5 ml HPM-Cryo):

Time (h)	0	1	2	3	4	5
Viability (%)	89.1	72.7	76.7	75.6	68.7	72.4

Recommended seeding density on collagen-coated plates:
24well plate – 500,000 cells/well
Use Corning collagen coated plates.
Culture in Human Hepatocyte Maintenance Medium (HHMM).

CYP P450 activity in culture after thawing: Ethoxyresorufin-O-deethylation: Induction with 25 µM β-naphthoflavone	pmol/ (mg x min) 17.6 ± 10.6	x-fold induction 3.0
<p>Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.</p> <p>Store at -150 °C or in the vapour phase of LN₂</p> <p>This product should be considered as potential biohazard. Only intended for <i>in vitro</i> use.</p>		
Issued by: A. Ullrich	Verified by: C. Garve	